• An advanced Phase II clinical-stage drug
• Activity previously seen in breast and gastric cancer patients in clinical trials
• Status: Phase II clinical trial protocol finalized; 12 trial sites identified, labs established to process patient samples
• IP: Patent protection through 2021
• Development / Registration Plan: Significantly increase likelihood of regulatory approval by using our diagnostic technology to identify clinical trial participants who will respond to therapy
• Relevant Biomarker: Thymidylate Synthase (TS) levels in circulating tumor cells (CTCs) will be monitored
• Estimated Market Potential: >$1B (for GI + breast + Head & Neck)
  

A liposomal formulation of a potent thymidylate synthase (TS) inhibitor

Obtained through a licensing agreement with OSI Pharmaceuticals in November 2007

Previously studied in approximately 150 patients in several Phase I and Phase II clinical trials